Obesity, cholesterol metabolism, and breast cancer pathogenesis

Cancer Research

Volumn 74, Issue 18, 2014, Pages 4976-4982

  McDonnell, Donald P ^a   Park, Sunghee ^a   Goulet, Matthew T ^a   Jasper, Jeff ^a   Wardell, Suzanne E ^a   Chang, Ching Yi ^a   Norris, John D ^a   Guyton, John R ^a   Nelson, Erik R ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

27-HYDROXYCHOLESTEROL; CHOLESTEROL; CHOLESTEROL DERIVATIVE;

BREAST TUMOR; FEMALE; HUMAN; LIPID METABOLISM; METABOLISM; OBESITY; PATHOLOGY; RISK FACTOR;

BREAST NEOPLASMS; CHOLESTEROL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; LIPID METABOLISM; OBESITY; RISK FACTORS;

EID: 84907487828     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1756     Document Type: Review

References (52)

1. Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat 2010;123:641-9.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311:806-14.
3. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008;114:71-83.
4. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 2013;19:6074-83.
5. Danilo C, Frank PG. Cholesterol and breast cancer development. Current Opinion in Pharmacology 2012;12:677-82.
6. Hu J, La Vecchia C, De Groh M, Negri E, Morrison H, Mery L, et al. Dietary cholesterol intake and cancer. Ann Oncol 2012;23:491-500.
7. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Annals of epidemiology 2008;18:671-7.
8. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. JNCI 2011;103:1461-68.
9. Hong CC, Shah AB, Jackowiak CM, Kossoff E, Fu H-W, Nimako GK, et al. Cholesterol drugs improve breast cancer prognosis in women with diabetes mellitus. Adv Pharmacoepidem Drug Safety 2013;2:130.
10. Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013;32:961-67.
11. Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, et al. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocrine-Related Cancer 2013;20:391-401.
12. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013;342:1094-8.
13. Hua X, Wu J, Goldstein JL, Brown MS, Hobbs HH. Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 1995;25:667-73.
14. Sun LP, Seemann J, Goldstein JL, Brown MS. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. Proc Natl Acad Sci U S A 2007;104:6519-26.
15. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterolregulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci U S A 2007;104:6511-8.
16. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009;325:100-4.
17. Zhang L, Reue K, Fong LG, Young SG, Tontonoz P. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler Thromb Vasc Biol 2012;32:2541-6.
18. Szanto A, Benko S, Szatmari I, Balint BL, Furtos I, Ruhl R, et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol Cell Biol 2004;24:8154-66.
19. Lange Y, Ory DS, Ye J, Lanier MH, Hsu FF, Steck TL. Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem 2008;283:1445-55.
20. Singh P, Saxena R, Srinivas G, Pande G, Chattopadhyay A. Cholesterol biosynthesis and homeostasis in regulation of the cell cycle. PLoS ONE 2013;8:e58833.
21. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008;134:97-111.
22. Smith B, Land H. Anticancer activity of the cholesterol exporter ABCA1 gene. Cell reports 2012;2:580-90.
23. McMurray HR, Sampson ER, Compitello G, Kinsey C, Newman L, Smith B, et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 2008;453:1112-16.
24. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002;11:467-74.
25. Du Sell CD, McDonnell DP. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends Pharmacol Sci 2008;29:510-4.
26. Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, et al. 27-hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Reports 2013;5:637-45.
27. Umetani M, Domoto H, Gormley A, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator that inhibits the cardiovascular effects of estrogen. Nature Med 2007;13:1185-92.
28. Du Sell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 2008;22:65-77.
29. McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 2010;10:620-8.
30. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 2010;396:63-6.
31. Han SI, Komatsu Y, Murayama A, Steffensen KR, Nakagawa Y, Nakajima Y, et al. Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/Liver X receptor pathway in mice. Hepatology 2013;59:1791-802.
32. Karuna R, Holleboom AG, Motazacker MM, Kuivenhoven JA, Frikke-Schmidt R, Tybjaerg-Hansen A, et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 2011;214:448-55.
33. Babiker A, Andersson O, Lund E, Xiu RJ, Deeb S, Reshef A, et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem 1997;272:26253-61.
34. Hansson M, Ellis E, Hunt MC, Schmitz G, Babiker A. Marked induction of sterol 27-hydroxylase activity and mRNA levels during differentiation of human cultured monocytes into macrophages. Biochim Biophys Acta 2003;1593:283-9.
35. Kim S-M, Lee S-A, Kim B-Y, Bae S-S, Eo S-K, Kim K. 27-hydroxycholesterol induces recruitment of monocytic cells by enhancing CCL2 production. Biochem Biophy Res Commun 2013;442:159-64.
36. Raccosta L, Fontana R, Maggioni D, Lanterna C, Villablanca EJ, Paniccia A, et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J Exp Med 2013;210:1711-28.
37. Torres CG, Ramirez ME, Cruz P, Epunan MJ, Valladares LE, Sierralta WD. 27-hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype. Oncol Rep 2011;26:389-97.
38. Baker ME. Origin and diversification of steroids: co-evolution of enzymes and nuclear receptors. Mol Cell Endocrinol 2011;334:14-20.
39. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 2009;124:698-712.
40. Lund E, Andersson O, Zhang J, Babiker A, Ahlborg G, Diczfalusy U, et al. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 1996;16:208-12.
41. Bjarnadottir O, Romero Q, Bendahl P-O, Jirstrom K, Ryden L, Loman N, et al. Targeting HMG-CoA reductase with statins in a window-ofopportunity breast cancer trial. Breast Cancer Res Treat 2013;138:499-508.
42. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995;31:9-27.
43. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-60.
44. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Int Med 2005;258:94-114.
45. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003;303:364-9.
46. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011;121:1163-73.
47. Young RJ, Coleman RE. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future oncology 2013;9:633-43.
48. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Aminobiphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438-46.
49. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Translational Med 2011;9:177.
50. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69:1624-32.
51. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
52. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, et al. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Molec Biol 1998;65:163-68.